Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats

Xenobiotica

Volumn 40, Issue 2, 2010, Pages 129-137

  Lee, Y S ^a   Choi, Y H ^a   Kim, T K ^b   Ryu, K H ^b   Lee, B Y ^b   Lee, M G ^a  

^a Seoul National University   (South Korea)

^b SK Chemicals   (South Korea)

Author keywords

And SK3544; Diabetes mellitus induced by streptozotocin; Hepatic and intestinal CYP isozymes; Mirodenafil; Pharmacokinetics; Rats; SK3541

Indexed keywords

CYTOCHROME P450 1A; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2D; CYTOCHROME P450 3A; DRUG METABOLITE; ENZYME INHIBITOR; MIRODENAFIL; MVIX; SILDENAFIL; SK3541; SK3544; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; LIVER BLOOD FLOW; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; ERECTILE DYSFUNCTION; INFUSIONS, INTRAVENOUS; MALE; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; SULFONAMIDES;

RATTUS;

EID: 75649115758     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903380975     Document Type: Article

References (37)

1. Ackerman DM, Leiman KC. (1977). Effect of experimental diabetes on drug metabolism in the rat, Drug Metab Dispos 5:405-410
2. Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. (2009). Pharmacokinetics of oltipraz in liver cirrhotic rats with diabetes mellitus. Br J Pharmacol 156:1019-1028
3. Barnett CR, Gilson GG, Wolf CR, Flatt PR, Ioannides C. (1990). Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem J 268:765-769
4. Barnett CR, Rudd S, Flatt PR, Ioannides C. (1993). Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins. Biochem Pharmacol 45:313-319
5. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
6. Chiou WL. (1978). Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549
7. Choi YH, Lee DC, Lee I, Lee MG. (2008a). Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci 97:5363-5375
8. Choi YH, Lee YS, Bae SH, Kim TK, Im GJ, Lee BY, Lee MG. (2008b). Dose-dependent pharmacokinetics, hepatic and gastrointestinal first-pass effects, and hepatic CYP isozymes responsible for metabolism of mirodenafil, a new erectogenic, in rats: involvement of CYP1A1/2, CYP2B1/2, CYP2D1, and CYP3A1/2.Paper presented at the 2008 Annual Convention of the Pharmaceutical Society of Korea, International Convention Center, Jeju, South Korea, 30 April-4 May, abst 344.
9. Choi YH, Lee YS, Kim TK, Im GJ, Lee BY, Lee MG. (2009a). Simultaneous LC-UV determination of 5-ethyl-2-{5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2- propoxyphenyl}-7-propyl-3,5-di-hydropyrrolo(3,2-d)pyrimidin-4-one(mirodenafil), and its two metabolites, SK3541 and SK3544, in rat plasma, urine, and various tissue homogenates. Chromatographia 69:677-683
10. Choi YH, Lee YS, Bae SH, Kim TK, Im GJ, Lee BY, Lee MG. (2009b). Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 30:305-317
11. Dong ZG, Hong JY, Ma QA, Li DC, Bullock J, Gonzalez FJ, Park SS, Gelboin HV, Yang CS. (1988). Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys 263:29-35.
12. Duggleby RG. (1995). Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 249:61-90.
13. Gibaldi M, Perrier D. (1982). Pharmacokinetics. 2nd Ed. New York (NY): Marcel-Dekker.
14. Ioannides C. (1996). Expression of cytochrome P450 protein in disease. In: Cytochrome P450. Metabolic and toxicological aspects. Boca Raton (FL): CRC Press. p. 301-327
15. Kaminsky LS, Zhang Q-Y. (2003). The small intestine as a xenobioticmetabolizing organ. Drug Metab Dispos 31:1520-1525
16. Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
17. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. (2005). Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-23.
18. Lee HS, Park EJ, Ji HY, Kim SY, Im G-J, Lee SM, Jang IJ. (2008). Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 38:21-33.
19. Lee J, Yoo HH, Rhim KJ, Sohn D-R, Kim D-H. (2007). Metabolism and excretion of 5-ethyl-2-{5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxy- phenyl}-7-propyl-3,5-dihydropyrrolo(3,2-d)-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrum 21:1139-1149
20. Lee JH, Lee MG. (2008). Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915-1924
21. Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640
22. Lewis DFV. (1996). P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, function, and mechanism. Bristol (PA): Taylor & Francis. p. 122-123
23. Ma Q, Dannan GA, Guengerich FP, Yang CS. (1989). Similarities and differences in the regulation of hepatic cytochrome P-450 enzymes by diabetes and fasting in male rats. Biochem Pharmacol 38:3179-3184
24. Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894
25. Mitruka BM, Rawnsley HM. (1982). Clinical biomedical and hematological reference values in normal experimental animals and normal humans. 2nd Ed. New York (NY): Masson.
26. Musicki B, Burnett AL. (2007). Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 19:129-138
27. Ogata M, Iizuka Y, Murata R, Hikichi N. (1996). Effect of streptozotocin-induced diabetes on cyclosporin A disposition in rats. Biol Pharm Bull 19:1586-90.
28. Pickup JC, Williams G. 1991. Textbook of diabetes,Vol. 1. Oxford (UK): Blackwell. p. 151-155
29. Raza H, Ahmed I, John A, Sharma AK. (2000). Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocininduced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol 14:131-139
30. Raza H, Ahmed I, Lakhani MS, Sharma AK, Pallot D, Montague W. (1996). Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol 52:1639-1642 (Pubitemid 26375470)
31. Reinke LA, Stohs SJ, Rosenberg H. (1978). Altered activity of hepatic mixed-function monooxygenase enzymes in streptozotocininduced diabetic rats. Xenobiotica 8:611-619
32. Sato H, Terasaki T, Okumura K, Tsuji A. (1991). Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocintreated diabetic rats. Pharm Res 8:563-569
33. Song BJ, Matsunaga T, Hardwick JP, Park SS, Veech RL, Yang CS, Gelboin HV, Gonzalez FJ. (1987). Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol 1:542-547
34. Thummel KE, Schenkman JB. (1990). Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol Pharmacol 37:119-129
35. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 55:77-85.
36. Watkins III JB, Sanders RA. (1995). Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 47:1-23.
37. Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390